These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36458707)

  • 21. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.
    Pitz AM; Yu F; Hermsen ED; Rupp ME; Fey PD; Olsen KM
    J Clin Microbiol; 2011 Jan; 49(1):269-74. PubMed ID: 20962147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular and Clinical Features of Heterogeneous Vancomycin-Intermediate
    Sreejisha M; Shenoy MS; Shenoy MS; Dhanashree B; Chakrapani M; Bhat KG
    Sultan Qaboos Univ Med J; 2023 Nov; 23(4):447-454. PubMed ID: 38090245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.
    Mather CA; Werth BJ; Sivagnanam S; SenGupta DJ; Butler-Wu SM
    J Clin Microbiol; 2016 Apr; 54(4):883-90. PubMed ID: 26763961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
    Asakura K; Azechi T; Sasano H; Matsui H; Hanaki H; Miyazaki M; Takata T; Sekine M; Takaku T; Ochiai T; Komatsu N; Shibayama K; Katayama Y; Yahara K
    PLoS One; 2018; 13(3):e0194212. PubMed ID: 29522576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.
    Horne KC; Howden BP; Grabsch EA; Graham M; Ward PB; Xie S; Mayall BC; Johnson PD; Grayson ML
    Antimicrob Agents Chemother; 2009 Aug; 53(8):3447-52. PubMed ID: 19506056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of heterogeneous vancomycin-intermediate
    Amberpet R; Sistla S; Sugumar M; Nagasundaram N; Manoharan M; Parija SC
    Indian J Med Res; 2019 Aug; 150(2):194-198. PubMed ID: 31670275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.
    Castro BE; Berrio M; Vargas ML; Carvajal LP; Millan LV; Rios R; Hernandez AK; Rincon S; Cubides P; Forero E; Dinh A; Seas C; Munita JM; Arias CA; Reyes J; Diaz L
    J Antimicrob Chemother; 2020 Sep; 75(9):2424-2431. PubMed ID: 32562543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006.
    Chung G; Cha J; Han S; Jang H; Lee K; Yoo J; Yoo J; Kim H; Eun S; Kim B; Park O; Lee Ys
    J Microbiol Biotechnol; 2010 Mar; 20(3):637-42. PubMed ID: 20372039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.
    Howden BP; Johnson PD; Ward PB; Stinear TP; Davies JK
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3039-47. PubMed ID: 16940100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
    Sun W; Chen H; Liu Y; Zhao C; Nichols WW; Chen M; Zhang J; Ma Y; Wang H
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3642-9. PubMed ID: 19546358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections.
    van Hal SJ; Jones M; Gosbell IB; Paterson DL
    PLoS One; 2011; 6(6):e21217. PubMed ID: 21713004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.
    Richter SS; Satola SW; Crispell EK; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Diekema DJ; Doern GV
    J Clin Microbiol; 2011 Dec; 49(12):4203-7. PubMed ID: 21976769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of vancomycin use trend change due to the availability of alternative antibiotics on the prevalence of Staphylococcus aureus with reduced vancomycin susceptibility: a 14-year retrospective study.
    Kang YR; Kim SH; Chung DR; Ko JH; Huh K; Cho SY; Kang CI; Peck KR
    Antimicrob Resist Infect Control; 2022 Aug; 11(1):101. PubMed ID: 35932086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C; Lin Y; Kornblum J; Lowy FD; Uhlemann AC
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus.
    Harigaya Y; Ngo D; Lesse AJ; Huang V; Tsuji BT
    BMC Infect Dis; 2011 Oct; 11():287. PubMed ID: 22026752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis.
    Shariati A; Dadashi M; Moghadam MT; van Belkum A; Yaslianifard S; Darban-Sarokhalil D
    Sci Rep; 2020 Jul; 10(1):12689. PubMed ID: 32728110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protein Biomarker Discovery for Methicillin-Sensitive, Heterogeneous Vancomycin-Intermediate and Vancomycin-Intermediate
    Liu YC; Lu JJ; Lin LC; Lin HC; Chen CJ
    J Proteome Res; 2021 Jan; 20(1):164-171. PubMed ID: 33058664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of Vancomycin Resistance among Methicillin-Resistant
    Pardo L; Mota MI; Parnizari A; Varela A; Algorta G; Varela G
    Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.